Metformin for Abdominal Aortic Aneurysm Growth Inhibition
Status:
Enrolling by invitation
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
A multi-centre population-based open-label randomized controlled trial with allocation
concealment and blinded outcome assessment will examine if up to 2g metformin daily slows AAA
growth in patients with small AAAs who do not have diabetes.